- Home
- OMH vs KPRX Comparison
OMH vs KPRX Comparison
Compare OMH & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- KPRX
- Stock Information
- Founded
- OMH 2015
- KPRX 1998
- Country
- OMH Singapore
- KPRX United States
- Employees
- OMH N/A
- KPRX N/A
- Industry
- OMH Real Estate
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OMH Finance
- KPRX Health Care
- Exchange
- OMH Nasdaq
- KPRX Nasdaq
- Market Cap
- OMH 9.1M
- KPRX 10.0M
- IPO Year
- OMH 2023
- KPRX N/A
- Fundamental
- Price
- OMH $0.51
- KPRX $3.68
- Analyst Decision
- OMH Strong Buy
- KPRX Strong Buy
- Analyst Count
- OMH 1
- KPRX 1
- Target Price
- OMH $1.50
- KPRX $10.00
- AVG Volume (30 Days)
- OMH 254.3K
- KPRX 53.2K
- Earning Date
- OMH 01-10-2025
- KPRX 11-08-2024
- Dividend Yield
- OMH N/A
- KPRX N/A
- EPS Growth
- OMH N/A
- KPRX N/A
- EPS
- OMH N/A
- KPRX 1.69
- Revenue
- OMH $5,390,607.00
- KPRX $16,020,000.00
- Revenue This Year
- OMH $101.90
- KPRX N/A
- Revenue Next Year
- OMH $38.34
- KPRX N/A
- P/E Ratio
- OMH N/A
- KPRX $2.14
- Revenue Growth
- OMH 25.77
- KPRX N/A
- 52 Week Low
- OMH $0.32
- KPRX $3.00
- 52 Week High
- OMH $6.00
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- OMH 69.54
- KPRX 60.53
- Support Level
- OMH $0.37
- KPRX $3.22
- Resistance Level
- OMH $0.43
- KPRX $3.36
- Average True Range (ATR)
- OMH 0.03
- KPRX 0.30
- MACD
- OMH 0.01
- KPRX 0.03
- Stochastic Oscillator
- OMH 100.00
- KPRX 61.24
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, Property Management Services, and revenue from emerging and other services.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.